Coronavirus Latest News

Australia set to host clinical trial of genetically modified Covid nasal spray vaccine

Australian company applies for permission to conduct trial of men and women aged 18 to 55

Australia is set to host the first human clinical trial of a genetically modified adenovirus vaccine for Covid-19 delivered via nasal spray.

Avance Clinical, an Australian contract research organisation, has applied to the office of the gene technology regulator for permission to conduct the phase 1 clinical trial on behalf US company Tetherex Pharmaceuticals Corporation.

Continue reading…

Read the original article at The Guardian

Related Articles

Back to top button